SCHEMBL5117310

SCHEMBL5117310

COc1cccc(CNC(=O)c2nc(C(N)C(=O)OCc3ccccc3)nc(O)c2O)c1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
MMP13 P45452 6/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.46
MAOB P27338 1/20 0.46
POLB P06746 1/20 0.45
APEX1 P27695 1/20 0.45
PTGER4 P35408 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5116009 0.88 S1PR4 (0.43) SMN1; SMN2ALDH1A1HPGDPOLB
SCHEMBL5253701 0.84 NPC1 (0.45) KDM4EALDH1A1HPGDHTTRAB9A
SCHEMBL5129741 0.84 PRSS1 (0.38) SMN1; SMN2ALDH1A1HPGDPOLB
SCHEMBL5127795 0.83 ADORA2A (0.43) ALDH1A1HPGD
SCHEMBL5123176 0.83 MAOB (0.45) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL5114308 0.83 THRB (0.41) SMN1; SMN2ALDH1A1HPGDLMNAHTT
SCHEMBL5113683 0.83 SMN1; SMN2 (0.52) SMN1; SMN2KDM4EUSP2ALDH1A1HPGD
SCHEMBL5118060 0.83 LMNA (0.47) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL5114012 0.83 HPGD (0.49) SMN1; SMN2KDM4EALDH1A1HPGDMMP13
SCHEMBL5129804 0.83 SMN1; SMN2 (0.48) SMN1; SMN2KDM4EUSP2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459452-B2 Dihydroxypyrimidine carboxamide inhibitors of HIV integrase ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2008-12-02 US disclosed
US-7232819-B2 Dihydroxypyrimidine carboxamide inhibitors of HIV integrase ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) 2007-06-19 US disclosed
US-20070083045-A1 Dihydroxypyrimidine carboxamide inhibitors of HIV integrase DI FRANCESCO MARIA E 2007-04-12 US disclosed
EP-1441734-B1 DIHYDROXYPYRIMIDINE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE ANGELETTI P IST RICHERCHE BIO (IT) 2007-02-28 EP disclosed
US-20050075356-A1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075356-A1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase DUT, DPYD, TYMP SMN1; SMN2 4143/4885KDM4E 414/4885USP2 3193/4885
US-20070083045-A1 Dihydroxypyrimidine carboxamide inhibitors of HIV integrase DUT, DPYD, TYMP SMN1; SMN2 4190/4885KDM4E 337/4885USP2 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.